Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone in patients with Mycosis Fungoides.
Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
This statement is based on a regulatory approval from the Health Canada:
ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |